Novonesis A/S – Adr ( (NVZMY) ) has released its Q3 earnings. Here is a breakdown of the information Novonesis A/S – Adr presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Novonesis A/S, a key player in the biosolutions industry, specializes in innovative solutions across sectors such as Food & Health and Planetary Health. The company has reported a strong performance in the first nine months of 2025, achieving an 8% organic sales growth and a robust adjusted EBITDA margin of 37.3%, despite facing significant currency headwinds. This growth was driven by solid performance across all sales areas, with particularly strong results in Emerging Markets and the Food & Health division, which saw a 9% organic sales growth. The company’s strategic focus on innovation and market expansion has been evident in its financial results, with net sales reaching EUR 3,161 million and an adjusted net profit increase of 22% compared to the previous year. The acquisition of the Feed Enzyme Alliance has also contributed positively to the company’s growth, enhancing its market position. Looking ahead, Novonesis expects to achieve a full-year organic sales growth of 7-8%, with continued focus on strategic priorities and market expansion to meet its 2030 targets.